

Table 15.10.1.7: Summary of PK Exposures from Pediatric Subjects in Study 337-1116 Compared with Adult Subjects in LDV/SOF Program
PK Lead-in Phase Intensive PK Analysis Set
Cohort 1 Subjects

12 to < 18 Years Old: LDV/SOF (90/400 mg)

Subject Population	GS-331007	
	AUCtau (h*ng/mL)	
Pediatric Population		
N	10	
Mean (SD)	12682.5 (1732.66)	
CV (%)	13.7	
Median	12340.9	
Min, Max	10039.8, 15323.0	
Geometric Mean	12575.8	
LDV/SOF NDA Adult Population		
N	2113	
Mean (SD)	12454.4 (3638.42)	
CV (%)	29.2	
Median	11892.6	
Min, Max	1788.8, 32000.0	
Geometric Mean	11954.7	
GMR (%): Pediatric Population/ LDV/SOF NDA Adult Population	105.20	
90% CI (%)	(90.61, 122.13)	

Note: LDV/SOF Adult Population = HCV-infected adult subjects administered LDV/SOF in Phase 2 and 3 studies.

Note: GMR = Geometric Mean Ratio.

Data Extracted: CRF Data: 26SEP2018, Lab Data: 25SEP2018.

Source: .../svr24/version1/prog/t-pkcomp.sas v9.4 Output file: t-pkcomp-p-a-cl.out 01OCT2018:20:29

Table 15.10.1.7: Summary of PK Exposures from Pediatric Subjects in Study 337-1116 Compared with Adult Subjects in LDV/SOF Program
PK Lead-in Phase Intensive PK Analysis Set
Cohort 1 Subjects

12 to < 18 Years Old: LDV/SOF (90/400 mg)

Subject Population (Continued)	LDV	SOF
	AUCtau (h*ng/mL)	AUCtau (h*ng/mL)
Pediatric Population		
N	10	10
Mean (SD)	10202.4 (5196.49)	2175.7 (578.92)
CV (%)	50.9	26.6
Median	9592.7	1989.6
Min, Max	4633.6, 23220.9	1366.1, 3195.6
Geometric Mean	9267.8	2106.4
LDV/SOF NDA Adult Population		
N	2113	1542
Mean (SD)	8533.8 (5190.84)	1375.8 (467.89)
CV (%)	60.8	34.0
Median	7163.0	1312.6
Min, Max	416.3, 49142.7	511.2, 6685.9
Geometric Mean	7287.1	1317.5
GMR (%): Pediatric Population/ LDV/SOF NDA Adult Population	127.18	159.88
90% CI (%)	(94.89, 170.45)	(137.89, 185.37)

Note: LDV/SOF Adult Population = HCV-infected adult subjects administered LDV/SOF in Phase 2 and 3 studies.

Note: GMR = Geometric Mean Ratio.

Data Extracted: CRF Data: 26SEP2018, Lab Data: 25SEP2018.

Source: .../svr24/version1/prog/t-pkcomp.sas v9.4 Output file: t-pkcomp-p-a-cl.out 01OCT2018:20:29

Table 15.10.2.7: Summary of PK Exposures from Pediatric Subjects in Study 337-1116 Compared with Adult Subjects in LDV/SOF Program
PK Lead-in Phase Intensive PK Analysis Set
Cohort 2 Subjects

6 to < 12 Years Old: LDV/SOF (45/200 mg)

GS-331007	
Subject Population	AUCtau (h*ng/mL)
Pediatric Population	
N	10
Mean (SD)	8210.3 (2542.42)
CV (%)	31.0
Median	7677.1
Min, Max	5071.5, 12511.6
Geometric Mean	7861.2
LDV/SOF NDA Adult Population	
N	2113
Mean (SD)	12454.4 (3638.42)
CV (%)	29.2
Median	11892.6
Min, Max	1788.8, 32000.0
Geometric Mean	11954.7
GMR (%): Pediatric Population/ LDV/SOF NDA Adult Population	65.76
90% CI (%)	(56.62, 76.37)

Note: LDV/SOF Adult Population = HCV-infected adult subjects administered LDV/SOF in Phase 2 and 3 studies.
Note: GMR = Geometric Mean Ratio.

Table 15.10.2.7: Summary of PK Exposures from Pediatric Subjects in Study 337-1116 Compared with Adult Subjects in LDV/SOF Program
PK Lead-in Phase Intensive PK Analysis Set
Cohort 2 Subjects

6 to < 12 Years Old: LDV/SOF (45/200 mg)

Subject Population (Continued)	LDV	SOF
	AUCtau (h*ng/mL)	AUCtau (h*ng/mL)
Pediatric Population		
N	10	9
Mean (SD)	7288.3 (4547.33)	1754.4 (419.18)
CV (%)	62.4	23.9
Median	6926.8	1684.8
Min, Max	2023.3, 15960.2	1017.7, 2303.8
Geometric Mean	5993.8	1705.9
LDV/SOF NDA Adult Population		
N	2113	1542
Mean (SD)	8533.8 (5190.84)	1375.8 (467.89)
CV (%)	60.8	34.0
Median	7163.0	1312.6
Min, Max	416.3, 49142.7	511.2, 6685.9
Geometric Mean	7287.1	1317.5
GMR (%): Pediatric Population/ LDV/SOF NDA Adult Population	82.25	129.48
90% CI (%)	(61.34, 110.30)	(110.79, 151.32)

Note: LDV/SOF Adult Population = HCV-infected adult subjects administered LDV/SOF in Phase 2 and 3 studies.

Note: GMR = Geometric Mean Ratio.

Table 15.10.3.7: Summary of PK Exposures from Pediatric Subjects in Study 337-1116 Compared with Adult Subjects in LDV/SOF Program
PK Lead-in Phase Intensive PK Analysis Set
Cohort 3 Subjects

3 to < 6 Years Old: LDV/SOF (45/200 mg or 33.75/150 mg)

Subject Population	GS-331007	
	AUCtau (h*ng/mL)	
Pediatric Population		
N	13	
Mean (SD)	11688.9 (3400.79)	
CV (%)	29.1	
Median	11391.2	
Min, Max	7742.1, 17732.4	
Geometric Mean	11246.9	
LDV/SOF NDA Adult Population		
N	2113	
Mean (SD)	12454.4 (3638.42)	
CV (%)	29.2	
Median	11892.6	
Min, Max	1788.8, 32000.0	
Geometric Mean	11954.7	
GMR (%): Pediatric Population/ LDV/SOF NDA Adult Population	94.08	
90% CI (%)	(82.51, 107.27)	

Note: LDV/SOF Adult Population = HCV-infected adult subjects administered LDV/SOF in Phase 2 and 3 studies.
Note: GMR = Geometric Mean Ratio.

Table 15.10.3.7: Summary of PK Exposures from Pediatric Subjects in Study 337-1116 Compared with Adult Subjects in LDV/SOF Program
PK Lead-in Phase Intensive PK Analysis Set
Cohort 3 Subjects

3 to < 6 Years Old: LDV/SOF (45/200 mg or 33.75/150 mg)

Subject Population (Continued)	LDV	SOF
	AUCtau (h*ng/mL)	AUCtau (h*ng/mL)
Pediatric Population		
N	13	3
Mean (SD)	9316.3 (3280.51)	2495.2 (412.64)
CV (%)	35.2	16.5
Median	8957.3	2260.1
Min, Max	4172.0, 15441.7	2253.9, 2971.7
Geometric Mean	8778.3	2473.7
LDV/SOF NDA Adult Population		
N	2113	1542
Mean (SD)	8533.8 (5190.84)	1375.8 (467.89)
CV (%)	60.8	34.0
Median	7163.0	1312.6
Min, Max	416.3, 49142.7	511.2, 6685.9
Geometric Mean	7287.1	1317.5
GMR (%): Pediatric Population/ LDV/SOF NDA Adult Population	120.46	187.76
90% CI (%)	(93.18, 155.73)	(143.41, 245.82)

Note: LDV/SOF Adult Population = HCV-infected adult subjects administered LDV/SOF in Phase 2 and 3 studies.

Note: GMR = Geometric Mean Ratio.